Austin Alley retweeted
I am officially in the Transfer Portal with 1 year of Eligibility:
(51 Career Starts)
2026 stats:
-41.5 yards per punt
-45% Inside the 20 yard line
-20% Inside the 3 yard line
The YouTube link to my film is below: youtu.be/oxPJgAAM9a4?is=zUtS…
$PEPG getting to this a little late in the midst of studying for an upcoming biochem final, but a great way to start the morning. Very encouraging results from this trial not only in splicing correction, but also wrt to vHOT which will continue to be a major point of contention after the Avidity debacle. Overall, after doing a short deep dive (again biochem final), these results are honestly much better than even I expected. They do lend credence to the idea that I postured in my attached post, backed by clinical research, about the steric hindrance being stoichiometric in nature.
I posited the idea that a cumulative effect would push the results (if not beat) of what we saw in the 15 mg/kg SAD readout, and largely I think it's fair to say that is true. Again, as has been previously mentioned you live and die by the small n, but these results are very promising for DM1. Exciting to see as a med student learning about disease and lack of treatment for many debilitating conditions!!
A speculative piece for the market. I can't claim to know what the price will do from here, though there are a few things to consider that seem to play in Pepgen's favor. First, in between the last readout and now Avidity failed, which was a competitor beating them to market that was acquired for a whopping $12 billion. Two, these results blow $DYN and Avidity splicing out of the water, but more importantly, after the Avidity burn I would assume there will be some resistance to longing Dyn, another DMPK degrader. Does some of that money funnel to Pepgen because as a steric blocker it has a different MoA that is backed by literature as being theoretically (and now maybe in practice too) more effective, again IDK. Happy to find and reference the paper if people want it.
A quick note as I did not do this deep dive myself. Super happy to have a great community of people to discuss medical literature and ideas with that push me to learn and apply the scientific process to its fullest extent, you know who you are.
Lastly, I'll make a comment on the @A_May_MD departure. He was a big part of my intro to the bioX community. Have always very much appreciated and respected his willingness to debate, share his ideas, and openly offer extensive due diligence. Adam you will be missed and openly welcomed back when that time comes.
Okay back to studying I go.
$PEPG
As we approach the readout 2H 2026, the more I read the more I am convinced that this is a compelling R/R setup.
First some background on PGN-EDODM1, its MoA, and why I think it could be successful in treating DM1. To start, it is a steric blocker that competitively binds the (CUG)exp, thereby inhibiting RNA-binding proteins and freeing MBNL1. This is in contrast to $DYN whose drug is an RNase H-recruiting gapmer that downregulates DMPK. The gapmer is much more effective at downregulating DMPK, though literature questions how strong the relationship is between downregulating DMPK and correcting alternative splicing events. This same paper provides evidence that steric blockers are actually more effective in displacing MBNL1 and achieving splicing correction.
Okay we had good SAD data, but what about the awful 5 mg/kg MAD data.
My two cents: the SAD data wasn't actually that good, barring the 15 mg/kg treatment group. I would say only the 15 mg/kg condition is demonstrating PoC and BiC potential. There is a plausible explanation for that. Unlike gapmers, steric hindrance is stoichiometric, requiring many more ASO molecules to achieve therapeutic effect. It seems as though the 5 and 10 mg/kg just don't reach the necessary threshold (10 mg/kg questionable). The muscular concentration of the drug at D28 of the 15 mg/kg Freedom SAD cohort was ~160 ng/g. This is at Day 28 after treatment on Day 1, meaning it is very likely that the treatment group sustained much higher muscle conc. levels than 160 ng/g beforehand. This is critically important for referencing the MAD 5 mg/kg readout.
The 5 mg/kg MAD readout:
At D7 following the last of four doses in this treatment group, the muscle conc. was about the same as the 15 mg/kg SAD cohort: 160 ng/g. This gives credence to the cumulative effect of multiple doses, given that the D28 reading for the 5 mg/kg SAD cohort was ~14 ng/g. At a time measured much closer to dosing (D7 compared to D28) and after 3 other doses, the muscle conc. were ~ the same. So, throughout the vast majority of this much longer trial the muscle conc. was significantly below the only treatment condition with PoC.
What does this mean for the upcoming 10 mg/kg readout? Through the cumulative dosing effect, this treatment group should achieve a peak muscle conc. higher the 15 mg/kg SAD cohort (whatever it was) and sustain it for longer than 28 days. Therefore, this treatment group should show very promising splicing correction and will be very telling on how effective PGN-EDODM1 truly is. If it misses, most likely a zero. If it demonstrates further BiC potential backed by literature that gives credibility to exactly that(with a cleaner safety profile), the risk-adjusted floor seems 2.5x+.
To touch on safety further, the safety concern is tied to the EDO delivery platform technology being positively charged and downregulating renal EGFR signaling. Pepgen has already used their EDO technology in a 10 mg/kg MAD trial with their EDO51 drug that was eventually deemed ineffective. There were safety signals in that trial, though it is my understanding that they were mild and would have been considered worth the tradeoff for treating either DMD or DM1. *I would link the photo but I've already used 4 photos so can send upon request.* The baseline assumption going into this readout should be those mild safety signals.
As always, not investment advice. And for trials with such small n, conviction is capped.
food for thought on a Thursday bc why not: Here is why I find game theory so fascinating, and this is largely unrelated to anything scientific in biotech (just me giving thoughts and procrastinating some anatomy studying). Seems possible some pod bros are targeting @A_May_MD and @seedy19tron. Could be for a variety of reasons not limited to Adam not mincing his words, especially for the pod bros; Seedy has a huge retail following; Seedy publishes extremely large short positions. Their large positions have been getting torched recently, and game theory suggests they will change their strat. Here are a few thought-provoking ways they might respond.
1. (Least favorite) They start hiding their book.
2. (I doubt they do one) They stop giving away any sizing of their book, or more specifically, hiding short positions (kind of like Kevin Mak). I am assuming the reason he doesn't publish his short book.
3. (My fav) They start faking out the pod bros by lying about sizing or position, only to put on the real trade post the move against their original position.
1
4
333
$PEPG up ~100% since this post. The edge as the price continues to rise decreases and the weight approximately doubled. @kevin__mak has some great materials on port management. Some of the chips should come off the table.
$PEPG
As we approach the readout 2H 2026, the more I read the more I am convinced that this is a compelling R/R setup.
First some background on PGN-EDODM1, its MoA, and why I think it could be successful in treating DM1. To start, it is a steric blocker that competitively binds the (CUG)exp, thereby inhibiting RNA-binding proteins and freeing MBNL1. This is in contrast to $DYN whose drug is an RNase H-recruiting gapmer that downregulates DMPK. The gapmer is much more effective at downregulating DMPK, though literature questions how strong the relationship is between downregulating DMPK and correcting alternative splicing events. This same paper provides evidence that steric blockers are actually more effective in displacing MBNL1 and achieving splicing correction.
Okay we had good SAD data, but what about the awful 5 mg/kg MAD data.
My two cents: the SAD data wasn't actually that good, barring the 15 mg/kg treatment group. I would say only the 15 mg/kg condition is demonstrating PoC and BiC potential. There is a plausible explanation for that. Unlike gapmers, steric hindrance is stoichiometric, requiring many more ASO molecules to achieve therapeutic effect. It seems as though the 5 and 10 mg/kg just don't reach the necessary threshold (10 mg/kg questionable). The muscular concentration of the drug at D28 of the 15 mg/kg Freedom SAD cohort was ~160 ng/g. This is at Day 28 after treatment on Day 1, meaning it is very likely that the treatment group sustained much higher muscle conc. levels than 160 ng/g beforehand. This is critically important for referencing the MAD 5 mg/kg readout.
The 5 mg/kg MAD readout:
At D7 following the last of four doses in this treatment group, the muscle conc. was about the same as the 15 mg/kg SAD cohort: 160 ng/g. This gives credence to the cumulative effect of multiple doses, given that the D28 reading for the 5 mg/kg SAD cohort was ~14 ng/g. At a time measured much closer to dosing (D7 compared to D28) and after 3 other doses, the muscle conc. were ~ the same. So, throughout the vast majority of this much longer trial the muscle conc. was significantly below the only treatment condition with PoC.
What does this mean for the upcoming 10 mg/kg readout? Through the cumulative dosing effect, this treatment group should achieve a peak muscle conc. higher the 15 mg/kg SAD cohort (whatever it was) and sustain it for longer than 28 days. Therefore, this treatment group should show very promising splicing correction and will be very telling on how effective PGN-EDODM1 truly is. If it misses, most likely a zero. If it demonstrates further BiC potential backed by literature that gives credibility to exactly that(with a cleaner safety profile), the risk-adjusted floor seems 2.5x+.
To touch on safety further, the safety concern is tied to the EDO delivery platform technology being positively charged and downregulating renal EGFR signaling. Pepgen has already used their EDO technology in a 10 mg/kg MAD trial with their EDO51 drug that was eventually deemed ineffective. There were safety signals in that trial, though it is my understanding that they were mild and would have been considered worth the tradeoff for treating either DMD or DM1. *I would link the photo but I've already used 4 photos so can send upon request.* The baseline assumption going into this readout should be those mild safety signals.
As always, not investment advice. And for trials with such small n, conviction is capped.
2
6
1,955
Happened to call the bottom on this one. DSMB great news… think it goes higher $PEPG
$PEPG
As we approach the readout 2H 2026, the more I read the more I am convinced that this is a compelling R/R setup.
First some background on PGN-EDODM1, its MoA, and why I think it could be successful in treating DM1. To start, it is a steric blocker that competitively binds the (CUG)exp, thereby inhibiting RNA-binding proteins and freeing MBNL1. This is in contrast to $DYN whose drug is an RNase H-recruiting gapmer that downregulates DMPK. The gapmer is much more effective at downregulating DMPK, though literature questions how strong the relationship is between downregulating DMPK and correcting alternative splicing events. This same paper provides evidence that steric blockers are actually more effective in displacing MBNL1 and achieving splicing correction.
Okay we had good SAD data, but what about the awful 5 mg/kg MAD data.
My two cents: the SAD data wasn't actually that good, barring the 15 mg/kg treatment group. I would say only the 15 mg/kg condition is demonstrating PoC and BiC potential. There is a plausible explanation for that. Unlike gapmers, steric hindrance is stoichiometric, requiring many more ASO molecules to achieve therapeutic effect. It seems as though the 5 and 10 mg/kg just don't reach the necessary threshold (10 mg/kg questionable). The muscular concentration of the drug at D28 of the 15 mg/kg Freedom SAD cohort was ~160 ng/g. This is at Day 28 after treatment on Day 1, meaning it is very likely that the treatment group sustained much higher muscle conc. levels than 160 ng/g beforehand. This is critically important for referencing the MAD 5 mg/kg readout.
The 5 mg/kg MAD readout:
At D7 following the last of four doses in this treatment group, the muscle conc. was about the same as the 15 mg/kg SAD cohort: 160 ng/g. This gives credence to the cumulative effect of multiple doses, given that the D28 reading for the 5 mg/kg SAD cohort was ~14 ng/g. At a time measured much closer to dosing (D7 compared to D28) and after 3 other doses, the muscle conc. were ~ the same. So, throughout the vast majority of this much longer trial the muscle conc. was significantly below the only treatment condition with PoC.
What does this mean for the upcoming 10 mg/kg readout? Through the cumulative dosing effect, this treatment group should achieve a peak muscle conc. higher the 15 mg/kg SAD cohort (whatever it was) and sustain it for longer than 28 days. Therefore, this treatment group should show very promising splicing correction and will be very telling on how effective PGN-EDODM1 truly is. If it misses, most likely a zero. If it demonstrates further BiC potential backed by literature that gives credibility to exactly that(with a cleaner safety profile), the risk-adjusted floor seems 2.5x+.
To touch on safety further, the safety concern is tied to the EDO delivery platform technology being positively charged and downregulating renal EGFR signaling. Pepgen has already used their EDO technology in a 10 mg/kg MAD trial with their EDO51 drug that was eventually deemed ineffective. There were safety signals in that trial, though it is my understanding that they were mild and would have been considered worth the tradeoff for treating either DMD or DM1. *I would link the photo but I've already used 4 photos so can send upon request.* The baseline assumption going into this readout should be those mild safety signals.
As always, not investment advice. And for trials with such small n, conviction is capped.
4
491
$PEPG
As we approach the readout 2H 2026, the more I read the more I am convinced that this is a compelling R/R setup.
First some background on PGN-EDODM1, its MoA, and why I think it could be successful in treating DM1. To start, it is a steric blocker that competitively binds the (CUG)exp, thereby inhibiting RNA-binding proteins and freeing MBNL1. This is in contrast to $DYN whose drug is an RNase H-recruiting gapmer that downregulates DMPK. The gapmer is much more effective at downregulating DMPK, though literature questions how strong the relationship is between downregulating DMPK and correcting alternative splicing events. This same paper provides evidence that steric blockers are actually more effective in displacing MBNL1 and achieving splicing correction.
Okay we had good SAD data, but what about the awful 5 mg/kg MAD data.
My two cents: the SAD data wasn't actually that good, barring the 15 mg/kg treatment group. I would say only the 15 mg/kg condition is demonstrating PoC and BiC potential. There is a plausible explanation for that. Unlike gapmers, steric hindrance is stoichiometric, requiring many more ASO molecules to achieve therapeutic effect. It seems as though the 5 and 10 mg/kg just don't reach the necessary threshold (10 mg/kg questionable). The muscular concentration of the drug at D28 of the 15 mg/kg Freedom SAD cohort was ~160 ng/g. This is at Day 28 after treatment on Day 1, meaning it is very likely that the treatment group sustained much higher muscle conc. levels than 160 ng/g beforehand. This is critically important for referencing the MAD 5 mg/kg readout.
The 5 mg/kg MAD readout:
At D7 following the last of four doses in this treatment group, the muscle conc. was about the same as the 15 mg/kg SAD cohort: 160 ng/g. This gives credence to the cumulative effect of multiple doses, given that the D28 reading for the 5 mg/kg SAD cohort was ~14 ng/g. At a time measured much closer to dosing (D7 compared to D28) and after 3 other doses, the muscle conc. were ~ the same. So, throughout the vast majority of this much longer trial the muscle conc. was significantly below the only treatment condition with PoC.
What does this mean for the upcoming 10 mg/kg readout? Through the cumulative dosing effect, this treatment group should achieve a peak muscle conc. higher the 15 mg/kg SAD cohort (whatever it was) and sustain it for longer than 28 days. Therefore, this treatment group should show very promising splicing correction and will be very telling on how effective PGN-EDODM1 truly is. If it misses, most likely a zero. If it demonstrates further BiC potential backed by literature that gives credibility to exactly that(with a cleaner safety profile), the risk-adjusted floor seems 2.5x+.
To touch on safety further, the safety concern is tied to the EDO delivery platform technology being positively charged and downregulating renal EGFR signaling. Pepgen has already used their EDO technology in a 10 mg/kg MAD trial with their EDO51 drug that was eventually deemed ineffective. There were safety signals in that trial, though it is my understanding that they were mild and would have been considered worth the tradeoff for treating either DMD or DM1. *I would link the photo but I've already used 4 photos so can send upon request.* The baseline assumption going into this readout should be those mild safety signals.
As always, not investment advice. And for trials with such small n, conviction is capped.
$NRIX further dilution way less likely, great partner adding to PoS, and more efficient pipeline particularly for international enrollment. How is this a bad thing? Am I missing something??
$NRIX more or less gives up half of its financial interest in most valuable pipeline asset for ~half its current market cap in upfront cash.
There were times when biotechs sold off hard on such news.
finance.yahoo.com/sectors/he…
1
5
851
$NRIX partnership w/ Roche 👏
globenewswire.com/news-relea…
1
423
$NKTR The market does not seem to love the recent raise. Are people considering the perspective that this is an increased bargaining chip in the suit against $LLY?
After the raise they have ~$1.1b cash which alleviates any cash pressure, meaning they have more than enough firepower to fund the highest quality resources to fight at trial and no incentive to settle cheaply. A strong footing already increases the 85%-90% the case settles.
It also increasingly shows demand for the company at a ~$3 billion mcap which only adds to the lost-value claim. 2024 reports estimated the settlement number between $250-$600 million. That number is undeniably higher now. Not a small number.
If you look at the Dermira acquisition, Lebri's commercial success, and degree to which REZPEG data was misrepresented, the read through to bad faith is rationally seamless for a jury.
If you don't want to take it from me, check out the 13G of Two Seas Capital that disclosed increasing their stake to 6.8% of $NKTR shares outstanding in Q1.
“Two Seas Capital LP seeks to generate outsized, uncorrelated returns through investments in events with a legal or regulatory catalyst.”
Disclosure: Long $NKTR
After another great year at Brown, I am in the transfer portal as a grad transfer with one year of eligibility
Career Accolades and Stats:
-All Ivy punter (HM)
-2nd in Ivy League Avg. Kickoff yards (2024)
-54.5% Touchbacks
Film Forthcoming
Grateful to receive an offer from UMass! @coachbenalbert @JuiceWa45
Blessed to share this award with my brothers!
Four Football Student-Athletes Named CSC Academic All-District
📰- bit.ly/3v5rPzk
#EverTrue
Austin Alley retweeted
I’ve officially entered myself into the transfer portal as a graduate transfer with 1 year of eligibility.
6’3 280lbs
OL/DL (Willing to Play Either)
Appeared in 29 games, 20 as an DL and started 9 games as an OL.
20 Tackles, 1 Sack
Austin Alley retweeted
I’ve officially put myself into the transfer portal as a graduate transfer with 1 year of eligibility left.
5’10” 195
Safety/Nickel/CB
All-Ivy League DB
20 Games (10 starts): 75 tackles; 2 TFL; 61 solo; 3 INT; 14 PBU
Film coming real soon..
Austin Alley retweeted
baller. and there’s nobody working harder than him either !
This quoted post is unavailable.
Austin Alley retweeted
Had a great time @BrownU_Football camp tonight. Thanks to @BrownHCPerry @Browncoachweave @CoachDjackson1 and all the coaches who attended for giving me a chance to perform for them. Had fun and learned a lot.
@GoMvb
@AustinAlley_

























